Maggie L. Shaw

The final podcast of our National Recovery Month series with UPMC Health Plan focused on the subject of trauma and knowledge of its impact on the behavioral health care space, as well as how both have facilitated positive change among […]

On September 20, the FDA approved isatuximab (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide (Revlimid; Celgene), and dexamethasone (VRd) in the first line for patients who have multiple myeloma and are ineligible for transplant. This approval came a full week

First set in 2014, the 90-90-90 program from UNAIDS had 3 goals: diagnose 90% of people living with HIV, provide antiretroviral therapy (ART) for 90% of diagnosed patients, and achieve viral suppression for 90% of patients on treatment.1 These goals

In less than a month, from August 20 to September 19, amivantamab (Ami; Rybrevant, Johnson & Johnson) received 2 approvals from the FDA for use in non–small cell lung cancer (NSCLC). Here we continue our discussion with Joshua K. Sabari,

Whether through typical coverage or a stand-alone drug plan, Medicare drug premiums will drop next year for most older Americans who are enrolled in traditional Medicare plans or Medicare Advantage plans. Announced on Friday, traditional Medicare drug premiums will go

September 30 marks LDL-C Awareness Day and brings both a conclusion to National Cholesterol Education Month as well as the launch of Cholesterol Connect. From the Family Heart Foundation, this novel and innovative combination of free at-home testing for blood

The accolades for amivantamab (Rybrevant; Johnson & Johnson) use against EGFR-mutated non–small cell lung cancer (NSCLC) have been many as of late, with 3 approvals from the FDA this year alone. In March, it was approved for first-line use in

In our podcast, “Uplifting Rural Communities,” Amy Herschell, PhD, associate vice president, Program Implementation and Evaluation, Community Care Behavioral Health Organization, and Jessica Meyers, MSEd, senior advisor for implementation, UPMC Center for High-Value Health Care, discussed the important grant-funded work

Osimertinib (Tagrisso; AstraZeneca) received its second new indication of the year, with yesterday’s FDA approval of the irreversible third-generation tyrosine kinase inhibitor (TKI) for use among adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR